NeuroMetrix Inc Cash Flow Conversion Efficiency
NeuroMetrix Inc cash flow conversion efficiency. Based on the latest financial reports, NeuroMetrix Inc (NURO) has a cash flow conversion efficiency ratio of -0.132x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.89 Million) by net assets ($14.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of NeuroMetrix Inc (2002–2024)
Cash flow conversion efficiency of NeuroMetrix Inc from 2002 to 2024. This chart illustrates how NeuroMetrix Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View NeuroMetrix Inc stock quote for real-time trading data and today's change.
NeuroMetrix Inc Cash Flow Conversion Ratio Explained
NeuroMetrix Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
NeuroMetrix Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NeuroMetrix Inc ranked by their cash flow conversion efficiency. Also see NeuroMetrix Inc (NURO) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Polygiene AB
ST:POLYG
|
0.000x |
|
Ostasiatiske Kompagni A/S
CO:OKEAC
|
0.523x |
|
HK Metals Utama Tbk PT
JK:HKMU
|
0.222x |
|
Fortune Rise Acquisition Corp
NASDAQ:FRLA
|
-0.009x |
|
China Aoyuan Group Limited
F:47C
|
-0.051x |
|
Check Cap Ltd
NASDAQ:CHEK
|
0.000x |
|
NetX Holdings Bhd
KLSE:0020
|
0.025x |
|
Ease2pay NV
AS:EAS2P
|
-0.009x |
Annual Cash Flow Conversion Efficiency for NeuroMetrix Inc (2002–2024)
The table below shows the annual cash flow conversion efficiency of NeuroMetrix Inc from 2002 to 2024. Review NURO free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $14.31 Million | $-7.13 Million | -0.498x | -64.46% |
| 2023-12-31 | $20.09 Million | $-6.08 Million | -0.303x | -33.73% |
| 2022-12-31 | $23.36 Million | $-5.29 Million | -0.226x | -153.54% |
| 2021-12-31 | $23.22 Million | $-2.07 Million | -0.089x | +77.32% |
| 2020-12-31 | $5.25 Million | $-2.07 Million | -0.394x | +72.48% |
| 2019-12-31 | $2.53 Million | $-3.62 Million | -1.431x | -404.96% |
| 2018-12-31 | $6.10 Million | $2.86 Million | 0.469x | +118.61% |
| 2017-12-31 | $5.02 Million | $-12.65 Million | -2.522x | +17.05% |
| 2016-12-31 | $4.96 Million | $-15.08 Million | -3.040x | -191.53% |
| 2015-12-31 | $12.56 Million | $-13.10 Million | -1.043x | +54.00% |
| 2014-12-31 | $3.39 Million | $-7.68 Million | -2.267x | -148.83% |
| 2013-12-31 | $7.19 Million | $-6.55 Million | -0.911x | +12.62% |
| 2012-12-31 | $8.80 Million | $-9.18 Million | -1.043x | -70.56% |
| 2011-12-31 | $11.09 Million | $-6.78 Million | -0.611x | +7.21% |
| 2010-12-31 | $20.20 Million | $-13.31 Million | -0.659x | -283.34% |
| 2009-12-31 | $35.71 Million | $-6.14 Million | -0.172x | +63.29% |
| 2008-12-31 | $22.83 Million | $-10.69 Million | -0.468x | -173.81% |
| 2007-12-31 | $46.73 Million | $-7.99 Million | -0.171x | -201.69% |
| 2006-12-31 | $43.41 Million | $7.30 Million | 0.168x | +219.38% |
| 2005-12-31 | $36.25 Million | $1.91 Million | 0.053x | +167.61% |
| 2004-12-31 | $34.06 Million | $-2.65 Million | -0.078x | -191.47% |
| 2003-12-31 | $-45.50 Million | $-3.87 Million | 0.085x | -25.46% |
| 2002-12-31 | $-39.93 Million | $-4.56 Million | 0.114x | -- |
About NeuroMetrix Inc
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing and sale of medical devices. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; and Quell, a wearable device for symptomatic relief and management of chronic pain. The company offers its products to managed endoc… Read more